

Change in Affibody's Nomination Committee for the 2024 Annual General Meeting

Stockholm, Sweden, March 19, 2024. Affibody Medical AB (publ) today announced a change of the composition of the Nomination Committee for the 2024 Annual General Meeting (AGM) to be held on May 16, 2024.

The composition of the Nomination Committee, appointed in accordance with the guidelines adopted by the Annual General Meeting on May 19, 2022, was announced on November 8, 2023. As a result of the death of one of the members, the composition of the Nomination Committee has changed. The Nomination Committee assesses that it is not necessary to replace the member since the work of the Nomination Committee is already well underway.

After the change the Nomination Committee for the 2024 AGM comprises the following members:

Malte St Cyr Ohm, Chair of the Nomination Committee, appointed by Dupa AB.
Mathias Uhlén, appointed by himself and closely related parties.

Robert Burns, Chair of the Board of Directors, will co-opt to the Nomination Committee.

The Nomination Committee's assignment is to present proposals regarding Chairman and other members of the Board, as well as remuneration to the Board's members, to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. The guidelines for the Nomination Committee are available on www.affibody.com.

About Affibody

Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules.

Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies.

Affibody's main shareholder Patricia Industries is a part of Investor AB.

Further information can be found at: www.affibody.com.

Contacts

Affibody

David Bejker, CEO, +46 706 454 948

Peter Zerhouni, CFO and CBO, +46 706 420 044

Affibody Media Contact

Richard Hayhurst/Ola Björkman, RHA Communications, +44 7711 821 527, richard@rhacomms.eu

Attachments

[Change in Affibody's Nomination Committee for the 2024 Annual General Meeting](#)